Filing Details

Accession Number:
0001140361-13-013358
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-03-20 15:39:10
Reporting Period:
2013-03-18
Filing Date:
2013-03-20
Accepted Time:
2013-03-20 15:39:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1274826 Robert Baffi C/O Biomarin Pharmaceutical Inc.
105 Digital Drive
Novato CA 94949
Evp, Technical Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-03-18 20,000 $14.39 72,350 No 4 M Direct
Common Stock Disposition 2013-03-18 20,000 $61.02 52,350 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Common Stock Disposition 2013-03-18 20,000 $0.00 20,000 $14.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 2009-11-12 2019-05-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,238 Indirect Shares held by Baffi Family Trust
Footnotes
  1. Transaction made pursuant to a Rule 10b5-1 plan executed on March 4, 2013.
  2. The price in Column 4 is a weighted average price. The prices actually received ranged from $61.00 to $61.10. The reporting person will provide to the issuer, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Options vest on November 12, 2009 and 1/48th on the 12th of each month thereafter.
  4. Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.